Faron completes cross‑border EUR 40.1 million rights offering to fund Phase II bexmarilimab trial

"Faron has completed a cross-border rights offering raising approximately EUR 40.1 million in Finland and the UK, fully covered by subscription undertakings, commitments and guarantees from shareholders and other investors. The proceeds will be used to strengthen the company’s finances, to fund a randomized 90‑patient Phase II frontline high‑risk myelodysplastic syndrome trial of bexmarilimab plus azacitidine, and to accelerate development of bexmarilimab through up to five investigator‑initiated trials. Roschier acted as Finnish law counsel for the transaction; the offering prospectus was prepared as an EU Follow‑on prospectus."